

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imricor Medical Systems, Inc.
ARBN	633 106 019

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Anita Messal
Date of last notice	27 May 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	14 May 2026
No. of securities held prior to change	<ul style="list-style-type: none"> - 391,864 shares of Class A common stock / CDIs - 38,340 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Class	Class A Common Stocks (Restricted Stock Units)
Number acquired	26,547
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash issue under Equity Incentive Plan (EIP)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> - 418,411 shares of Class A common stock / CDIs - 38,340 options with an exercise price of US\$1.57 per share of Class A common stock and an expiry date of 7 May 2031 (US time).
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue under EIP as approved at AGM on 8 May 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	N/A
---	-----

For personal use only

+ See chapter 19 for defined terms.